Skip to main content

Precision BioSciences Appoints Juli Blanche as Chief People Officer

New Senior Executive Brings 25 Years of Human Resources Leadership and Pharma Industry Experience

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Juli Blanche has been appointed Chief People Officer and a member of the senior leadership team at Precision BioSciences. Ms. Blanche is a human resources (HR) executive with over 25 years of strategic business partnership and enterprise leadership experience in the pharmaceutical and financial services industries. She most recently joins Precision BioSciences from Bristol-Myers Squibb (BMS) where she was Senior Vice President and HR Business Partner, Global Commercialization.

This press release features multimedia. View the full release here:

Juli Blanche joins gene editing company Precision BioSciences as newly appointed Chief People Officer. (Photo: Business Wire)

Juli Blanche joins gene editing company Precision BioSciences as newly appointed Chief People Officer. (Photo: Business Wire)

“We are very excited to welcome Juli to Precision BioSciences and our senior leadership team,” said Michael Amoroso, Chief Executive Officer of Precision BioSciences. “In this newly created position, Juli will add tremendous HR leadership that will help Precision continue to be a dynamic place where our gene editing business as well as our outstanding employees can thrive and grow.”

“I am thrilled to join Precision BioSciences and to build on the company’s already exceptional passion and drive to improve life through the development of gene editing medicines,” said Ms. Blanche. “I am impressed and inspired by the team of Precisioneers here, and the people-focused culture built on a foundation of innovation and scientific discovery that values collaboration and perseverance. I look forward to working closely with Michael and the senior leadership team to make Precision BioSciences one of the greatest places to work, and help the Company fulfill its mission to improve life through cutting-edge science and transformative medicine.”

Prior to joining Precision BioSciences, Juli was with BMS where she held several roles, each with increasing global responsibility. Most recently as SVP, HR Business Partner, Global Commercial she was the strategic HR Partner to the Chief Commercial Officer overseeing a workforce of 11,000 people, including a global HR workforce of more than 100 people. In a prior role as Vice President, Global Talent Strategy and Talent Acquisition, Juli led a team of more than 200 people responsible for recruiting 16,000 people over two years during the pandemic. She also built the global talent organization for the new BMS as part of the merger integration with Celgene and Juno. While at Celgene, Juli was Vice President, Global Talent Acquisition and Employee Experience where she designed and developed employee engagement initiatives inclusive of the company’s Diversity and Inclusion strategy and employee/executive onboarding. Prior to Celgene, she previously held senior level positions responsible for global HR transformation projects and new leadership development and transition programs for newly appointed leaders in the organization. Juli previously spent 10 years working in financial markets with Morgan Stanley, managing their HR, IT and Operations. Juli earned her Bachelor of Arts in Communications and Business from Marist College.

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple ex vivo “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.